- In Vivo Originals
- Featured Topics
Leadership
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
-
Interviews
Stelo Launch And Dispelling GLP-1s: Dexcom’s Sayer Speaks
By Barnaby PickeringDexcom’s CEO, Kevin Sayer, ahead of this year’s Advanced Technologies & Treatments for Diabetes conference, shared an update on the company’s recent news, future strategy and where he feels the market is headed.
-
Interviews
20 Voices: What Does 2024 Hold For Biopharma?
By Eleanor Malone20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
-
Interviews
International Women’s Day – An Opportunity To Consider Some Of The Shared And Disparate Challenges Faced By Women In Our Sector
By Barnaby PickeringFriday, 8 March is International Women’s Day, and to celebrate, Citeline spoke to female leaders from across the medtech sector about their experiences as women, women-specific issues that technology can address, and how they can empower others to reach similar – or even greater – levels of success. Take a look at some interview snapshots below:
-
Interviews
Finding Value Left On The Shelf: Karuna Case Study
By Lucie Ellis-TaittPureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
-
Data
Execs On The Move: January 2024
By Barnaby PickeringAn interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
-
Interviews
Climate Compliance For Medtech Businesses: ‘Tactical Changes Are Not Enough’
By Ashley YeoHealth care businesses seeking to reconcile positive climate action with business growth must combine long-term thinking and short-term actions. Only then will they achieve internal and external sustainability goals, says Robert Metzke, Royal Philips’ SVP and global head of sustainability.
-
Interviews
Bayer’s BD And Licensing Strategy Key To Moving Through Difficult Period
By David WildAs Bayer moves through a challenging period, business development, licensing and impact investment may help buttress the company’s resilience.
-
Analysis
Philips Doubles Down On ESG And AI While Servicing Respironics Recall Priority
By Ashley YeoRoyal Philips CEO Roy Jakobs used the company’s 2023 results conference to update the market on the agile operating plan 2023-2025 and US actions to address the Respironics recall. Investors’ lively interest in the recall meant that strategic themes concerning environmental sustainability and future health care dividends from artificial intelligence platforms were all but sidelined.
-
Interviews
Roche's Partnership Playbook: A Closer Look At 2023's Successes And 2024's Prospects
By David WildAfter chasing late-stage assets in 2023, Roche is moving back to its more diverse dealmaking approach. The company’s global head of pharma partnering, James Sabry, spoke to In Vivo about the value of partnerships at Roche and the formula for a successful collaboration.
-
Analysis
Immortalizing Janet Woodcock
By M. Nielsen HobbsOffering a regulatory Mt. Rushmore to place the outgoing principal deputy commissioner in historical context.
-
Interviews
BD Moves The Needle To High Growth Segments
By Ashley YeoBecton Dickinson is investing in high-growth segments and is on a mission to simplify its business. CEO Tom Polen’s 2025 strategy targets 25% operating margin from both innovations and durable core business combined, as senior BD executives told In Vivo during a break at J.P. Morgan 2024.
-
Analysis
AstraZeneca’s Net Zero Ambitions Factor In AI, Green Gas And Renewables
By Ashley YeoAstraZeneca was among the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative’s corporate net zero standard. Investment in green gas, reforestation and the associated use of AI mark the company out as a thought leader in sustainability initiatives. In this context, COP28’s renewed focus on ‘climate+health’ is well timed.
-
News
Execs On The Move: December 2023
By Barnaby PickeringAn interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
-
Interviews
Stark Warnings For Pharma On Preserving Trust And Overcoming Risk Aversion
By Lucie Ellis-TaittIndustry veteran Jeremy Levin, the 2023 winner of the Scrip Awards Lifetime Achievement Award, speaks to In Vivo about what holds back innovation in the biopharma industry, new technologies and commitments needed to protect the future relationship between drug developers and patients.
-
Interviews
Vision And Resilience, The Hallmarks Of Axel Hoos’ Leadership Approach
By David WildAxel Hoos helped create the field of immuno-oncology and now has his sights on proving the worth of Scorpion Therapeutics’ precision oncology platform. The executive spoke with In Vivo about company culture, the Scorpion strategy and resilience in the face of resistance.
-
Interviews
VC Exec Talks M&A And 2024 Expectations
By Lucie Ellis-TaittVC Playbook: Hubert Birner, managing partner for Montreal and Munich, is responsible for TVM Capital Life Science’s overall investment approach and global fund operations. At the November 2023 BIO-Europe conference, he sat down with In Vivo to discuss the VC’s strategy and expectations for the European life science sector in 2024.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.